Amgen Reports Results From Phase 3 PRIME 203 Trial For Vectibix
Amgen has reported that the Phase 3 PRIME 203 trial evaluating Vectibix (panitumumab) administered in combination with Folfox (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.